TABLE 5

Cumulative excretion and retention of radioactivity after single intravenous and oral doses of 14C-DB289 to rats and cynomolgus monkeys

Results are expressed as mean percentage radioactive dose.



Rat

Monkey
Biological Sample (Collection Time) Intravenous (1 mg/kg)
Oral (10 mg/kg)
Oral (50 mg/kg)
Intravenous (1 mg/kg)
Oral (5 mg/kg)

Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Urine
0-24 h 4.4 3.5 3.0 4.3 2.2 3.0 6.1 7.1 1.1 1.0
0-168 h 5.7 4.8 4.0 5.4 2.8 3.8 8.4 10.2 2.0 1.9
Feces
0-24 h 28.8 18.7 50.1 37.1 59.2 48.9 5.6 2.6 30.1 12.5
0-168 h 55.2 36.0 72.5 66.2 79.5 70.4 24.6 23.1 70.2 69.5
Total excretion a (0-168 h) 60.9 40.8 76.5 71.6 82.3 74.2 33.0 33.3 72.2 71.4
Liver (168 h) 22.4 41.4 12.9 21.3 5.6 16.3 40.0b 41.9b 11.1b 11.4b
GIT (168 h) 2.0 1.6 1.7 1.6 0.9 0.9 N.M. N.M. N.M. N.M.
Carcass (168 h) 8.4 8.9 8.6 7.7 4.2 5.0 N.M. N.M. N.M. N.M.
Total retention (168 h) 32.8 51.9 23.2 30.6 10.7 22.2 41.2 c 42.9 c 11.5 c 11.7 c
Total recovery (168 h)
93.7
92.7
99.5
102.2
93.0
96.4
74.2
76.2
83.7
83.1
  • GIT, gastrointestinal tract; N.M., not measured.

  • a Total excretion results for urine include cage washings for both rat and monkey, and results for feces include cage debris (mainly uneaten food contaminated with excreta) for monkeys only.

  • b Forty-three days postdose (monkeys only).

  • c Total retention at 43 days postdose in monkeys includes the kidneys, heart, lungs, and GIT wall (which totaled 1.0-1.3% of dose after intravenous administration and 0.3-0.4% of dose after oral administration), but not the remaining carcass (which was not measured).